Clinical Trial Update: Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study of the intravenous agent S65487 in relapsed or refractory hematologic cancers (acute myeloid leukemia, non-Hodgkin lymphoma, multiple myeloma, and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• S65487

Snippet

Sponsor: Institut de Recherches Internationales Servier | Conditions: Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Non-Hodgkin Lymphoma | Phase 1 | Status: TERMINATED